MODDERN

Personalized medicine proponents have revived legislation seeking to improve the reimbursement system for diagnostics and to incentivize the development of companion tests that pick out best responders to drugs.

Originally published Oct. 1.
A new bill strongly supported within the diagnostics industry could put pressure on the Centers for Medicare & Medicaid Services to alter its procedures for setting reimbursement rates for molecular diagnostics.

Representative Leonard Lance (R-NJ) recently introduced a bill that includes proposals for enhancing the reimbursement system for diagnostic tests, as well as incentives for pharmaceutical firms to revive unapproved drugs in their pipelines as treatments for unmet medical need.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.